Study finds COVID monoclonal antibody causes far fewer side effects than vaccines, promising safer protection.

Invivyd's recent research shows that their low-dose monoclonal antibody, adintrevimab, causes significantly fewer early side effects compared to COVID-19 mRNA and protein vaccines. Data from the EVADE trial revealed only 2% of subjects experienced moderate to severe systemic side effects within seven days, versus over 80% for vaccines in a separate study. This suggests monoclonal antibodies could offer a safer alternative for COVID-19 prevention, especially for vulnerable populations. Invivyd plans a head-to-head LIBERTY trial to further compare safety and tolerability between their antibody candidate VYD2311 and mRNA vaccines, aiming to provide more tolerable protection options.